Personalized medicine: The impact on chemistry

Therapeutic Delivery

Volumn 1, Issue 5, 2010, Pages 651-665

  Watkins, John ^a   Marsh, Andrew ^a   Taylor, Paul C ^a   Singer, Donald R J ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THIOPURINE METHYLTRANSFERASE;

BINDING SITE; CLINICAL CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SUSTAINED RELEASE FORMULATION;

EID: 79953668817     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.64     Document Type: Review

References (133)

1. Bates S. Progress towards personalized medicine. Drug Discov. Today 15(3-4), 115-120 (2010).
2. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 4(5), 426-427 (1999). (Pubitemid 29508743)
3. Marburger JH III, Kvamme Ef. President's Council of Advisors on Science and Technology. Priorities for Personalized Medicine. Office of Science Technology and Policy. Washington, DC, USA (2008).
4. Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur. J. Cancer 40(17), 2623-2632 (2004). (Pubitemid 39487084)
5. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet 375(9725), 1525-1535 (2010).
6. Bottinger EP. Foundations, promises and uncertainties of personalized medicine. Mount Sinai J. Med. 74(1), 15-21 (2007). (Pubitemid 46957751)
7. Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14(Spec No. 2), R207-R214 (2005). (Pubitemid 41631889)
8. Edwards Ir, Aronson Jk. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356(9237), 1255-1259 (2000).
9. Kucherlapati R. Raju Kucherlapati talks about personalised medicine: breathing new life into old drugs. Interview by Steve Carney. Drug Discov. Today 12(7-8), 272-275 (2007).
10. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329(7456), 15-19 (2004). (Pubitemid 38869995)
11. Weatherall D. Royal Society Working Group on Pharmacogenetics. Personalised medicines: hopes and realities. Royal Society, London, UK (2005).
12. Mitri Z, Esmerian MO, Simaan JA, Sabra R, Zgheib NK. Pharmacogenetics and personalized medicine: the future for drug prescribing. J. Med. Liban. 58(2), 101-104 (2010).
13. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 2(8038), 584-586 (1977). (Pubitemid 8176607)
14. Hansen T, Petersen N, Iitia A, Blaabjerg O, Hyltoft-Petersen P, Horder M. Robust nonradioactive oligonucleotide ligation assay to detect a common point mutation in the cyp 2d6 gene causing abnormal drug metabolism. Clin. Chem. 41(3), 413-418 (1995).
15. Gerd M, Johanna W. Influence of cyp 2d6 genetics on opioid kinetics, metabolism and response. Curr. Pharmacogenomics 3, 43-52 (2005).
16. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome p450 2d6 (cyp 2d6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6-13 (2004). (Pubitemid 40220611)
17. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol. 64(8), 753-767 (2008).
18. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine s-methyltransferase. Mol. Pharmacol. 47(6), 1141-1147 (1995).
19. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine s-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126(8), 608-614 (1997). (Pubitemid 27172187)
20. Ford LT, Berg JD. Thiopurine s-methyltransferase (tpmt ) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J. Clin. Pathol. 63(4), 288-295 (2010).
21. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine s-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in caucasians. Am. J. Hum. Genet. 58(4), 694-702 (1996). (Pubitemid 26086658)
22. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine s-methyltransferase gene in African-Americans. Hum. Mol. Genet. 8(2), 371-376 (1999). (Pubitemid 29054281)
23. Hardy J, Singleton A. Genomewide association studies and human disease. N. Engl. J. Med. 360(17), 1759-1768 (2009).
24. Cronin S, Tomik B, Bradley DG, Slowik A, Hardiman O. Screening for replication of genome-wide snp associations in sporadic als . Eur. J. Hum. Genet. 17(2), 213-218 (2008).
25. Wang WYS, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat. Rev. Genet. 6(2), 109-118 (2005). (Pubitemid 40179533)
26. Mccarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9(5), 356-369 (2008). (Pubitemid 351556063)
27. Yang L, Chen J, He L. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput. Biol. 5(7), e1000441 (2009).
28. Yang L, Luo H, Chen J, Xing Q, He L. Sepresa: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res. 37(Suppl. 2), W406-412 (2009).
29. Macdonald Ml, Lamerdin J, Owens S, et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2(6), 329-337 (2006). (Pubitemid 43787215)
30. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7(2), 99-111 (2006).
31. Taube J, Halsall D, Baglin T. Influence of cytochrome p-450 cyp 2c9 polymorphisms on warfarin sensitivity and risk of overanticoagulation in patients on long-term treatment. Blood 96(5), 1816-1819 (2000). (Pubitemid 30661066)
32. Wadelius M, Chen LY, Downes K, et al. Common vkorc 1 and ggc x polymorphisms associated with warfarin dose. Pharmacogenomics J. 5(4), 262-270 (2005). (Pubitemid 41131718)
33. Sconce EA, Khan TI, Wynne HA, et al. The impact of cyp 2c9 and vkorc1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005). (Pubitemid 41510803)
34. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of cyp 2c9 and vkorc1 - rationale and perspectives. Thromb. Res. 120(1), 1-10 (2007). (Pubitemid 46601582)
35. Landefeld CS, Ohio Lee G. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87(2), 144-152 (1989). (Pubitemid 19201634)
36. Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 249(3), 374-378 (1983). (Pubitemid 13167236)
37. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N. Engl. J. Med. 345(20), 1444-1451 (2001).
38. Amstutz HC, Friscia DA, Dorey F, Carney BT. Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement. J. Bone Joint Surg. 71(3), 321-326 (1989). (Pubitemid 19116681)
39. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
40. Wosilait WD, Ryan MP, Byington KH. Competition between serum albumin and soluble fraction of liver for binding of warfarin and other drugs. Res. Commun. Chem. Pathol. Pharmacol. 32(1), 113-121 (1981). (Pubitemid 11156485)
41. Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy 25(2), 303-307 (2005). (Pubitemid 40227466)
42. Sands CD, Chan ES, Welty TE. Revisiting the significance of warfarin protein-binding displacement interactions. Ann. Pharmacother. 36(10), 1642-1644 (2002).
43. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and inr data to refine warfarin dosing. Clin. Pharmacol. Ther. 87(5), 572-578 (2010).
44. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 cyp 2c9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999). (Pubitemid 29103806)
45. Kalow W. Pharmacogenetics and personalised medicine. Fundamen. Clin. Pharmacol. 16(5), 337-342 (2002). (Pubitemid 35356942)
46. Nadejde C, Creanga DE, Humelnicu I, Filip E, Dorohoi DO. Study on the intermolecular interactions in rifampicin ternary solutions - calculation of microscopic parameters of rifampicin molecules. J. Mol. Liq. 150(1-3), 51-55 (2009).
47. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cdna and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299(3), 849-857 (2001). (Pubitemid 33104951)
48. Emil F, George PC. Dose: a critical factor in cancer chemotherapy. Am. J. Med. 69(4), 585-594 (1980).
49. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R. Chromogenic in situ hybridization analysis of her -2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin®) therapy. Path. Int. 51(8), 579-584 (2001).
50. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 7(5), 548-552 (2001). (Pubitemid 32448320)
51. Sui W, Ou M, Chen J, et al. Comparison of immunohistochemistry (ihc ) and fluorescence in situ hybridization (fish ) assessment for her-2 status in breast cancer. World J. Surg. Onc. 7(1), 83 (2009).
52. Peterson RT. Chemical biology and the limits of reductionism. Nat. Chem. Biol. 4(11), 635-638 (2008).
53. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (gr 43175), selectively blocks neurogenic plasma extravasation from blood vessels in Dura Mater. Br. J. Pharmacol. 99(1), 202-206 (1990). (Pubitemid 20033811)
54. Kaufmann SH. Paul Ehrlich. Founder of chemotherapy. Nat. Rev. Drug Discov. 7(5), (2008)
55. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4(11), 682-690 (2008).
56. Kitano H. Biological robustness. Nat. Rev. Genet. 5(11), 826-837 (2004). (Pubitemid 39457498)
57. Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today 12(3-4), 156-160 (2007). (Pubitemid 46176667)
58. Frantz S. Drug discovery: playing dirty. Nature 437(7061), 942-943 (2005).
59. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12(1-2), 34-42 (2007). (Pubitemid 46014485)
60. Hopkins AL. Network pharmacology. Nat. Biotech. 25(10), 1110-1111 (2007). (Pubitemid 47538107)
61. Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet. 15(7), 267-272 (1999). (Pubitemid 29317711)
62. Dipple KM, Mccabe ERB. Modifier genes convert 'simple' Mendelian disorders to complex traits. Mol. Genet. Metab. 71(1-2), 43-50 (2000).
63. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol. Syst. Biol. 3, 140 (2007).
64. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science 324(5933), 1394-1395 (2009).
65. Pujol A, Mosca R, Farrés J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol. Sci. 31(3), 115-123 (2010).
66. Pache RA, Zanzoni A, Naval J, Mas JM, Aloy P. Towards a molecular characterisation of pathological pathways. FEBS Lett 582(8), 1259-1265 (2008).
67. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol. Assess. 11(51), 1 (2007).
68. Rovati GE, Sala A, Capra V, Dahlèn S-E, Folco G. Dual coxib/tp antagonists: a possible new twist in nsaid pharmacology and cardiovascular risk. Trends Pharmacol. Sci. 31(3), 102-107 (2010).
69. Mani KM, Lefebvre C, Wang K, et al. A systems biology approach to prediction of oncogenes and molecular perturbation targets in b-cell lymphomas. Mol. Syst. Biol. 4, 169 (2008).
70. Mestres J, Gregori-Puigjané E. Conciliating binding efficiency and polypharmacology. Trends Pharmacol. Sci. 30(9), 470-474 (2009).
71. Chen B, Wild D, Guha R. Pubchem as a source of polypharmacology. J. Chem. Inf. Model. 49(9), 2044-2055 (2009).
72. Koch MA, Schuffenhauer A, Scheck M, et al. Charting biologically relevant chemical space: a structural classification of natural products (sconp ). Proc. Natl Acad. Sci. USA 102(48), 17272-17277 (2005). (Pubitemid 41740856)
73. Colley C, Lucas L. Polypharmacy. J. Gen. Intern. Med. 8(5), 278-283 (1993).
74. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J. Am. Acad. Nurse Pract. 17(4), 123-132 (2005).
75. Dickstein K, Cohen-Solal A, Filippatos G, et al. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. Heart J. 29(19), 2388-2442 (2008).
76. Levy ML, Thomas M, Small I, Pearce L, Pinnock H, Stephenson P. Summary of the bts/sign british guideline on the management of asthma. Prim. Care Respir. J. 18(Suppl. 1), S1-S16 (2009).
77. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326(7404), 1419 (2003).
78. Reddy Ks. The preventive polypill - much promise, insufficient evidence. N. Engl. J. Med. 356(3), 212 (2007).
79. Janga SC, Tzakos A. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. Mol. Biosyst. 5(12), 1536-1548 (2009).
80. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley Pm. Complex formation of human papillomavirus e7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8(13), 4099-4105 (1989). (Pubitemid 20066852)
81. Kramer H, Han C, Post W, et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the multiethnic study of atherosclerosis (mesa ). Am. J. Hypertens. 17(10), 963-970 (2004). (Pubitemid 39361670)
82. Rösler A, Vandermeulen GWM, Klok H-A. Advanced drug delivery devices via selfassembly of amphiphilic block copolymers. Adv. Drug Deliv. Rev. 53(1), 95-108 (2001). (Pubitemid 33152835)
83. Chung JE, Yokoyama M, Yamato M, Aoyagi T, Sakurai Y, Okano T. Thermoresponsive drug delivery from polymeric micelles constructed using block copolymers of poly(n-isopropylacrylamide) and poly(butylmethacrylate). J. Control. Release 62(1-2), 115-127 (1999). (Pubitemid 29486490)
84. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combinationdisease- modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 46(4), 894-898 (2002). (Pubitemid 34303799)
85. O'connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers. Arch. Intern. Med. 166(17), 1802-1804 (2006).
86. Cappuccio FP, Markandu ND, Tucker FA, Macgregor GA. Dose-response and length of action of nifedipine capsules and tablets in patients with essential-hypertension - a randomized crossover study. Eur. J. Clin. Pharmacol. 30(6), 723-725 (1986). (Pubitemid 16018954)
87. Kostarelos K, Miller AD. Synthetic, selfassembly abcd nanoparticles; a structural paradigm for viable synthetic nonviral vectors. Chem. Soc. Rev. 34(11), 970-994 (2005). (Pubitemid 41619247)
88. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48(21), 6523-6543 (2005). (Pubitemid 41504710)
89. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9(10), 430-431 (2004). (Pubitemid 38510559)
90. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 10(11) (Suppl. 17), 1-20 (2005).
91. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (cp-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 275(1), 101-113 (1995).
92. Fura A. Role of pharmacologically active metabolites in drug discovery and development. Drug Discov. Today 11(3-4), 133-142 (2006). (Pubitemid 43375964)
93. Andrew JSC. Omapatrilat - the story of overture and octave. Int. J. Cardiol. 86(1), 1-4 (2002).
94. Heudi O, Ramirez-Molina C, Marshall P, et al. Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ace/nep inhibitors gw 660511x and omapatrilat. J. Pept. Sci. 8(11), 591-600 (2002). (Pubitemid 35402309)
95. Garcia-Robles R, Villabla F, Gonzalez-Albarran O, et al. Effects of omapatrilat on blood pressure and the progression of renal failure in an experimental model of Type 2 diabetes mellitus. Am. J. Hypertens. 13(S2), 36A-36A (2000).
96. Boix F. Vasopeptidase inhibitors: a bradykinin link. Lancet 359(9312), 1157-1158 (2002).
97. Lehar J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotech. 27(7), 659-666 (2009).
98. Gautam CS, Saha L. Fixed dose drug combinations (FDCS): rational or irrational. A view point. Br. J. Clin. Pharmacol. 65(5), 795-796 (2008). (Pubitemid 351535085)
99. Herrick TM, Million RP. Tapping the potential of fixed-dose combinations. Nat. Rev. Drug Discov. 6(7), 513-514 (2007). (Pubitemid 47019440)
100. Hogan JE. Hydroxypropylmethylcellulose sustained release technology. Drug Dev. Ind. Pharm. 15(6), 975-999 (1989). (Pubitemid 19199639)
101. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes, Obes. Metab. 11(4), 338-342 (2009).
102. Heller J, Pangburn SH, Penhale DWH. Use of bioerodible polymers in self-regulated drug delivery systems. In: Controlled-Release Technology. American Chemical Society, Washington, DC, USA 172-187 (1987).
103. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem. Rev. 99(11), 3181-3198 (1999). (Pubitemid 129583051)
104. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew. Chem. Int. Edit. 48(5), 872-897 (2009).
105. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6(9), 688-701 (2006). (Pubitemid 44286001)
106. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 22(1), 119-124 (1999). (Pubitemid 29028307)
107. Inzucchi SE. Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. JAMA 287(3), 360-372 (2002). (Pubitemid 34256388)
108. Graham DJ, Ouellet-Hellstrom R, Macurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 304(4), 411-418 (2010).
109. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170(14), 1191-1201 (2010).
110. Cohen D. FDA puts rosiglitazone postmarketing trial on hold. BMJ 341, c4017 (2010).
111. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4(1), 35-44 (2005). (Pubitemid 40109588)
112. Leslie BJ, Hergenrother PJ. Identification of the cellular targets of bioactive small organic molecules using affinity reagents. Chem. Soc. Rev. 37(7), 1347-1360 (2008).
113. Spring DR. Chemical genetics to chemical genomics: small molecules offer big insights. Chem. Soc. Rev. 34(6), 472-482 (2005). (Pubitemid 40880427)
114. Vegas AJ, Fuller JH, Koehler AN. Smallmolecule microarrays as tools in ligand discovery. Chem. Soc. Rev. 37(7), 1385-1394 (2008).
115. Peddibhotla S, Dang Y, Liu JO, Romo D. Simultaneous arming and structure/activity studies of natural products employing O-H insertions: an expedient and versatile strategy for natural products-based chemical genetics. J. Am. Chem. Soc. 129(40), 12222-12231 (2007). (Pubitemid 47556858)
116. Kanoh N, Kumashiro S, Simizu S, et al. Immobilization of natural products on glass slides by using a photoaffinity reaction and the detection of protein-small-molecule interactions. Angew. Chem. Int. Ed. 42(45), 5584-5587 (2003). (Pubitemid 37509360)
117. Dilly SJ, Bell MJ, Clark AJ, et al. A photoimmobilisation strategy that maximises exploration of chemical space in small molecule affinity selection and target discovery. Chem. Commun. (Camb.) (27), 2808-2810 (2007). (Pubitemid 47035562)
118. Ladwa SR, Dilly SJ, Clark AJ, Marsh A, Taylor PC. Rapid identification of a putative interaction between b2-adrenoreceptor agonists and atf 4 using a chemical genomics approach. ChemMedChem 3(5), 742-744 (2008).
119. Dilly SJ, Beecham MP, Brown SP, et al. Novel tertiary amine oxide surfaces that resist nonspecific protein adsorption. Langmuir 22(19), 8144-8150 (2006). (Pubitemid 44412571)
120. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 321(5886), 263-266 (2008). (Pubitemid 351989100)
121. Scheiber J, Jenkins JL, Sukuru SCK, et al. Mapping adverse drug reactions in chemical space. J. Med. Chem. 52(9), 3103-3107 (2009).
122. Woodcock J. The prospects for 'personalized medicine' in drug development and drug therapy. Clin. Pharmacol. Ther. 81(2), 164-169 (2007). (Pubitemid 46174812)
123. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001). (Pubitemid 32165345)
124. Rual JF, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human proteinprotein interaction network. Nature 437(7062), 1173-1178 (2005). (Pubitemid 41509356)
125. Stelzl U, Worm U, Lalowski M, et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 122(6), 957-968 (2005). (Pubitemid 41345212)
126. Ewing RM, Chu P, Elisma F, et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol. 3, 89 (2007).
127. Charbonnier S, Gallego O, Gavin AC. The social network of a cell: recent advances in interactome mapping. Biotechnol. Annu. Rev. 14, 1-28 (2008). (Pubitemid 351916583)
128. Lehar J, Stockwell BR, Giaever G, Nislow C. Combination chemical genetics. Nat. Chem. Biol. 4(11), 674-681 (2008).
129. Barden CJ, Weaver DF. The rise of micropharma. Drug Discov. Today 15(3-4), 84-87 (2010).
130. Mertens-Talcott SU, Zadezensky I, De Castro WV, Derendorf H, Butterweck V. Grapefruit-drug interactions: can interactions with drugs be avoided? J. Clin. Pharmacol. 46(12), 1390-1416 (2006). (Pubitemid 44704201)
131. Corey E, Czakó B, Kürti L. Molecules and Medicine. Wiley, Hoboken, NJ, USA (2007).
132. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov. Today 10(2), 139-147 (2005). (Pubitemid 40247812)
133. NASA: The Pioneer Missions. www.nasa.gov/centers/ames/missions/archive/ pioneer.html (Accessed 7 September 2010)